

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER Food and Drug Administration, ORA OPQO HQ 12420 Parklawn Drive, RM 2032 Rockville, MD 20857 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 09/24/2018-09/28/2018
	FEI NUMBER 3004081307

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Ashwin Upasane, Site Head

FIRM NAME Cipla Limited	STREET ADDRESS Verna Industrial Estate
CITY, STATE AND ZIP CODE Verna, Salcette, Goa 403722, India	TYPE OF ESTABLISHMENT INSPECTED Drug Manufacturer

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

Observation 1

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing. Specifically,


The proposed commercial master batch record for the production of (b) (4) Tablets, (b) (4), version 01, does not provide written instructions for the removal of the (b) (4) from a (b) (4) bag inside your IPCs (In Process Containers) and the subsequent pouring of this (b) (4) back into the same IPC as needed for docking with your compression systems.

Observation 2

Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up. Specifically,

A change to production instructions was implemented prior to completion of all corrective action changes related with a deviation. Namely, as part of Deviation DEV-1006-2017-00073 for (b) (4) Tablets, USP (b) (4) ng lot (b) (4) (AQL non-compliance for minor defects), a Remedial Action item was initiated for the revision to the "Inspection by Attributes for Inprocess Checks of (b) (4) Tablets" form to modify defect type "Minor spots" to "Minor spots (Other than (b) (4) Spots)".

This Remedial Action was completed with revised form implemented on Nov. 21, 2017, and before the approval of the concurrent proposal under Change Request 1006-P-18-00004 (initiated on January 10, 2018) for the change in the product labeling (Pack Insert) for (b) (4) Tablets, USP to include "Due to inherent nature of formulation, occasionally, (b) (4) spots may be present on tablet surface. This does not affect efficacy of the product".

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Nicole E. Knowlton, Investigator Rebecca Dombrowski, Consumer Safety Officer Pei-I Chu, Chemist	DATE ISSUED 09/28/2018
--------------------------	--	---	---------------------------